PURPOSE:Topiramate (TPM) is a novel drug with broad antiepileptic effect in children and adults. In vitro studies suggest activity as sodium-channel blocker, as gamma-aminobutyric acid type A (GABAA)-receptor agonist and as non-N-methyl-D-aspartate (NMDA)-glutamate receptor antagonist. METHODS: With transcranial magnetic stimulation (TMS), we evaluated which of the mechanisms of action of TPM detected in vitro are relevant for the modulation of human motor cortex excitability. In a double-blind, placebo-controlled, crossover study design, we investigated the effect of single oral doses of 50 mg and 200 mg TPM on motor thresholds, cortical silent period (CSP), and on intracortical inhibition (ICI) and intracortical facilitation (ICF) in 20 healthy subjects. RESULTS: A significant dose-dependent increase of ICI was noticed after 200 mg TPM as compared with placebo at short interstimulus intervals of 2 to 4 ms. TPM had no effect on motor thresholds or the CSP. CONCLUSIONS: We conclude that a single dose of TPM selectively increases ICI by GABAAergic and/or glutamatergic mechanisms without a relevant influence on measures, depending on ion-channel blockade or GABAB-receptor activity. The decrease of intracortical excitability (as measured by ICI and ICF) caused by TPM may correlate with its lack of proconvulsive potential in idiopathic generalized epilepsy, because drugs without this action or with less pronounced action may exacerbate seizures in this condition.
RCT Entities:
PURPOSE:Topiramate (TPM) is a novel drug with broad antiepileptic effect in children and adults. In vitro studies suggest activity as sodium-channel blocker, as gamma-aminobutyric acid type A (GABAA)-receptor agonist and as non-N-methyl-D-aspartate (NMDA)-glutamate receptor antagonist. METHODS: With transcranial magnetic stimulation (TMS), we evaluated which of the mechanisms of action of TPM detected in vitro are relevant for the modulation of human motor cortex excitability. In a double-blind, placebo-controlled, crossover study design, we investigated the effect of single oral doses of 50 mg and 200 mg TPM on motor thresholds, cortical silent period (CSP), and on intracortical inhibition (ICI) and intracortical facilitation (ICF) in 20 healthy subjects. RESULTS: A significant dose-dependent increase of ICI was noticed after 200 mg TPM as compared with placebo at short interstimulus intervals of 2 to 4 ms. TPM had no effect on motor thresholds or the CSP. CONCLUSIONS: We conclude that a single dose of TPM selectively increases ICI by GABAAergic and/or glutamatergic mechanisms without a relevant influence on measures, depending on ion-channel blockade or GABAB-receptor activity. The decrease of intracortical excitability (as measured by ICI and ICF) caused by TPM may correlate with its lack of proconvulsive potential in idiopathic generalized epilepsy, because drugs without this action or with less pronounced action may exacerbate seizures in this condition.
Authors: Janine Reis; Leonardo G Cohen; Phillip L Pearl; Brita Fritsch; Nikolai H Jung; Irene Dustin; William H Theodore Journal: Neurology Date: 2012-06-20 Impact factor: 9.910
Authors: M Inghilleri; F Gilio; A Conte; V Frasca; C Marini Bettolo; E Iacovelli; B Gregori; M Prencipe; A Berardelli Journal: Exp Brain Res Date: 2006-08-05 Impact factor: 1.972
Authors: A Laine Green; Pengfei Gu; Milena De Felice; David Dodick; Michael H Ossipov; Frank Porreca Journal: Cephalalgia Date: 2013-12-11 Impact factor: 6.292
Authors: A Münchau; J M Langosch; W Gerschlager; J C Rothwell; M Orth; M R Trimble Journal: J Neurol Neurosurg Psychiatry Date: 2005-04 Impact factor: 10.154
Authors: Matthias Zunhammer; Berthold Langguth; Michael Landgrebe; Elmar Frank; Sabine Müller; Julia Burger; Philipp G Sand; Peter Eichhammer; Göran Hajak Journal: Psychopharmacology (Berl) Date: 2010-12-16 Impact factor: 4.530